BridgeBio Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring at BridgeBio Pharma, Inc.'s 2026 Annual Meeting of Stockholders held on June 22, 2026. The report was filed on June 26, 2026. The filing primarily addresses corporate governance matters, including director elections, executive compensation votes, and amendments to equity incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance data.
Material Changes and Corporate Actions
- Board Resignation: Dr. Randal W. Scott resigned as a Class I director effective June 22, 2026, upon the completion of his term. The resignation was not due to any disagreement with the Company.
- Director Elections: Stockholders elected three new Class I directors to serve until the 2029 Annual Meeting: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D.
- Equity Plan Amendment: Stockholders approved an amendment to the 2021 Stock Option and Incentive Plan, increasing the number of shares reserved for issuance by 2,000,000.
- Accounting Firm Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
Out of 195,806,242 shares entitled to vote, 175,706,357 shares were present or represented by proxy. Key voting outcomes include:
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation (152,949,577 For vs. 6,938,080 Against).
- Compensation Frequency: Stockholders voted to hold future advisory votes on executive compensation every 1 Year (154,371,970 votes for 1 Year).
- Equity Plan Approval: The amendment to increase share reserves received 132,402,786 votes For, 27,350,537 votes Against, and 1,353,547 Abstentions.
Management noted that the next required vote on the frequency of compensation advisory votes will occur no later than the 2032 annual meeting.
Investor Verification Checklist
- Verify the specific terms of the 2,000,000 share increase in the 2021 Stock Option and Incentive Plan (Exhibit 10.1).
- Review the definitive proxy statement filed on April 24, 2026, for detailed biographies of the newly elected directors.
- Confirm the impact of the new director composition on board committee assignments.
- Monitor future filings for the Company's financial results for the fiscal year ending December 31, 2026, as this 8-K contains no financial data.